Key result
An unglycosylated 38-kDa form of the HCV E2 envelope protein was identified in the cytosol, where it interacts with PKR and is stabilized by interferon-alpha, potentially contributing to HCV resistance.
Population
Human embryonic kidney HEK-293T cells and HeLa cells
Comparison
Transfection with HCV E2 protein, treatment with… vs Empty vector transfection or untreated cells
Design
Preclinical
Authors
Loading...
Potential HCV interferon resistance mechanism identified in animal models; leaves open clinical relevance and therapeutic targeting in humans.
The study identifies a novel unglycosylated cytosolic form of the HCV E2 protein that interacts with PKR, potentially contributing to HCV resistance to interferon-alpha.
Pavio et al. (2002) studied Hepatitis C virus (HCV) infection. HCV E2 envelope protein expression and IFN-alpha treatment vs. Untreated cells or empty vector was evaluated on Detection, subcellular localization, and PKR interaction of unglycosylated E2 protein. An unglycosylated 38-kDa form of the HCV E2 envelope protein was identified in the cytosol, where it interacts with PKR and is stabilized by interferon-alpha, potentially contributing to HCV resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: